| PTI | pancreatic trypsin inhibitor; persistent tolerant infection; Pictorial Test of Intelligence; placent... |
|---|---|
| STI | Scientific and Technical Information; serum trypsin inhibitor; soybean trypsin inhibitor; systolic t... |
| ELT | Euglobulin Lysis Time |
| ATLS | acute tumor lysis syndrome; advanced trauma life support |
| BLT | bleeding time; blood-clot lysis time; blood test |
| reactive schizophrenia | Those forms of severe schizophrenic disorders which are distinguished from process schizophrenia by their more acute onset, greater relation to environmental stress, and better prognosis. (05 Mar 2000) |
|---|---|
| child reactive disorders | Reactions to an event or set of events which are considered to be of pathological degree, that have not developed into a neurosis, psychosis, or personality disorder with fixed patterns. (12 Dec 1998) |
| cold-reactive antibody | See: cold agglutinin. (05 Mar 2000) |
| C-reactive protein | <protein> This blood test is used as an indicator of acute inflammation. C-reactive protein is a protein of the pentraxin family, produced by the liver during periods of inflammation and detectable in serum in various disease conditions particularly during the acute phase of immune response. Normally C-reactive protein should be negative in the bloodstream. C-reactive protein is synthesised by hepatocytes and its production may be triggered by prostaglandin E1 or parogen. It consists of five polypeptide sub units forming a molecule of total molecular weight 105 kD. It binds to polysaccharides present in a wide range of bacterial, fungal and other cell walls or cell surfaces and to lecithin and to phosphoryl or choline containing molecules. It is related in structure to Serum Amyloid. And C polysaccharide. Conditions which can cause a positive C-reactive protein include: rheumatoid arthritis, lupus, pneumococcal pneumonia, rheumatic fever, cancer, tuberculosis and myocardial infarction. A positive C-reactive protein may also be seen in the later half of pregnancy and in some who are taking birth control pills. See: acute phase proteins (06 Oct 1997) |
| cross-reactive antibody | <haematology, immunology> Antibodies which don't respond to any one specific antigen, but will respond to a number of them. These antibodies can be responsible for false positive results in antigen-antibody tests. (09 Oct 1997) |
| thiobarbituric acid reactive substances | Low-molecular-weight end products, probably malondialdehyde, that are formed during the decomposition of lipid peroxidation products. These compounds react with thiobarbituric acid to form a fluorescent red adduct. (12 Dec 1998) |
| a1-trypsin inhibitor | A glycoprotein that is the major protease inhibitor of human serum, is synthesised in the liver, and is genetically polymorphic due to the presence of over 20 alleles; individuals appropriately homozygous are deficient in a1-trypsin and are predisposed to pulmonary emphysema and juvenile hepatic cirrhosis because of alterations in the amino acid and sialic acid components of the glycoprotein. A1-Antitrypsin also inhibits thrombin. Synonym: a1-trypsin inhibitor, human a1-proteinase inhibitor. (05 Mar 2000) |
| ACE inhibitor | <pharmacology> A group of antihypertensive medications that work by inhibiting an enzyme (angiotensin-converting enzyme) that is important in the regulation of blood pressure. Studies have also indicated that it may help prevent or slow the progression of kidney disease in patients with diabetes. Examples include: captopril, ramipril, enalapril, losartan potassium, bepridil and lisinopril. (12 Mar 1998) |
| aldose reductase inhibitor | <pharmacology> A class of drugs being studied as a way to prevent eye and nerve damage in people with diabetes. Aldose reductase is an enzyme that is normally present in the eye and in many other parts of the body. It helps change glucose (sugar) into a sugar alcohol called sorbitol. Too much sorbitol trapped in eye and nerve cells can damage these cells, leading to retinopathy and neuropathy. Drugs that prevent or slow (inhibit) the action of aldose reductase are being studied as a way to prevent or delay these complications of diabetes. (09 Oct 1997) |
| angiotensin-converting enzyme inhibitor | <pharmacology> A class of drugs used in the treatment of hypertension and heart failure. They exert their haemodynamic effect mainly by inhibiting the renin-angiotensin system and produce a reduction of peripheral arterial resistance. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (14 Aug 2000) |
| aromatase inhibitor | Drugs, such as aminoglutethimide, that inhibit aromatase, an enzyme used in the synthesis of oestrogens. (05 Mar 2000) |
| beta-lactamase inhibitor | <pharmacology> Drugs such as clavulanic acid, which are used to inhibit bacterial beta-lactamases; often used with a penicillin or cephalosporin to overcome drug resistance. (05 Mar 2000) |
| Bowman-Birk inhibitor | A polypeptide that will inhibit both trypsin and chymotrypsin. (05 Mar 2000) |
| C1 esterase inhibitor | An a2-neuraminoglycoprotein that inhibits the enzymatic activity of C1 esterase, the activated first component of complement. A deficiency of this inhibitor results in a lack of inhibition of C1r and C1s leading to uncontrolled activation of the complement cascade and oedema. (05 Mar 2000) |
| carbonate dehydratase inhibitor | An agent, usually chemically related to the sulfonamides, that inhibits the activity of carbonate dehydratase, producing a general decrease in the formation of H2CO3 in the tissues. See: acetazolamide, dichlorphenamide. Synonym: carbonic anhydrase inhibitor. (05 Mar 2000) |